Skip to main content

Table 1 Patient and treatment characteristics

From: Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era

 

Total (n = 336)

3D-CRT (n = 186)

IMRT (n = 150)

P*

Age, years, median (range)

58 (16–79)

59 (16–79)

56 (16–79)

0.004

Sex, n (%)

 Female

149 (44.3)

96 (51.6)

53 (35.3)

0.003

 Male

187 (55.7)

90 (48.4)

97 (64.7)

 

KPS, n (%)

  ≤ 70

172 (51.2)

104 (55.9)

68 (45.3)

0.156

 80

82 (24.4)

41 (22)

41 (27.3)

 

  ≥ 90

82 (24.4)

41 (22)

41 (27.3)

 

Extent of resection, n (%)

 Total

206 (61.3)

109 (58.6)

97 (64.7)

0.009

 Subtotal/Partial

108 (32.1)

70 (37.6)

38 (25.3)

 

 Biopsy

22 (6.5)

7 (3.8)

15 (10)

 

IDH1 mutation, n (%)

 No

250 (74.4)

117 (62.9)

133 (88.7)

< 0.001

 Yes

18 (5.4)

6 (3.2)

12 (8)

 

 unknown

68 (20.2)

63 (33.9)

5 (3.3)

 

MGMT, n (%)

 Unmethylated

212 (63.1)

115 (61.8)

97 (64.7)

0.592

 Methylated

124 (36.9)

71 (38.2)

53 (35.3)

 

Subventriclular zone, n (%)

 Uninvolved

206 (61.3)

122 (65.6)

84 (56)

0.073

 Involved

130 (38.7)

64 (34.4)

66 (44)

 

PTV1 volume, cm3, median (range)

403 (71–1080)

422 (74–1080)

375 (71–1041)

<.001

PTV2 volume, cm3, median (range)

113 (6–475)

119 (12–475)

103 (6–468)

0.002

Total dose, Gy, median (range)

60 (41–72.5)

60 (54–70)

60 (41–72.5)

0.073

No. of fractionation, median (range)

30 (15–35)

30 (23–35)

30 (15–33)

<.001

Baseline TLC, /μL, median (range)

1370 (300–3740)

1365 (300–3740)

1385 (410–3640)

0.648

Baseline TLC, /μL, n (%)

  < 1000

81 (24.1)

45 (24.2)

36 (24)

0.893

  ≥ 1000

255 (75.9)

141 (75.8)

114 (76)

 

The cumulative dose of temozolomidea, mg/m2, median (range)

3588 (722–6267)

3497 (856–6267)

3684 (722–5599)

0.117

  1. Abbreviations: 3D-CRT three-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, KPS Karnofsky performance status, PTV planning target volume, TLC total lymphocyte count
  2. *P-values were calculated for the comparison of the 3D-CRT and IMRT groups
  3. aThe cumulative doses of temozolomide for 3 months from the start of chemoradiation were calculated